Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2028.
Senate Floor Amendment No. 1: Replaces everything after the enacting clause. Amends the Illinois Insurance Code. Makes changes to defined terms. Includes an annual screening (rather than surveillance tests) for ovarian cancer for insureds who are at risk for ovarian cancer using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, and (iii) pelvic examination (rather than only for insureds who are at risk for ovarian cancer) in provisions requiring coverage without cost sharing. Provides that a group policy of accident and health insurance that provides coverage for hospital or medical treatment or services for illness on an expense-incurred basis and is amended, delivered, issued, or renewed on or after January 1, 2028 shall, in addition to specified coverage, provide coverage for all medically viable methods for the detection and diagnosis of ovarian cancer for insureds who are at risk for ovarian cancer. Provides that the coverage may be subject to a deductible, coinsurance, or other cost sharing. Effective January 1, 2028.

Statutes affected:
Introduced: 215 ILCS 5/356
Engrossed: 215 ILCS 5/356
Enrolled: 215 ILCS 5/356